4//SEC Filing
OrbiMed Capital GP VI LLC 4
Accession 0001144204-19-045296
CIK 0001773427other
Filed
Sep 18, 8:00 PM ET
Accepted
Sep 19, 7:12 PM ET
Size
16.1 KB
Accession
0001144204-19-045296
Insider Transaction Report
Form 4
ORBIMED ADVISORS LLC
10% Owner
Transactions
- Conversion
Series A Convertible Preferred Stock
2019-09-17−6,078,103→ 0 total(indirect: See footnote)→ Common Stock (6,078,103 underlying) - Conversion
Series B Convertible Preferred Stock
2019-09-17−1,053,204→ 0 total(indirect: See footnote)→ Common Stock (1,053,204 underlying) - Conversion
Common Stock
2019-09-17+6,078,103→ 6,078,103 total(indirect: See footnote) - Purchase
Common Stock
2019-09-17$18.00/sh+275,000$4,950,000→ 7,406,307 total(indirect: See footnote) - Conversion
Common Stock
2019-09-17+1,053,204→ 7,131,307 total(indirect: See footnote)
OrbiMed Capital GP VI LLC
10% Owner
Transactions
- Conversion
Common Stock
2019-09-17+1,053,204→ 7,131,307 total(indirect: See footnote) - Conversion
Series A Convertible Preferred Stock
2019-09-17−6,078,103→ 0 total(indirect: See footnote)→ Common Stock (6,078,103 underlying) - Conversion
Common Stock
2019-09-17+6,078,103→ 6,078,103 total(indirect: See footnote) - Purchase
Common Stock
2019-09-17$18.00/sh+275,000$4,950,000→ 7,406,307 total(indirect: See footnote) - Conversion
Series B Convertible Preferred Stock
2019-09-17−1,053,204→ 0 total(indirect: See footnote)→ Common Stock (1,053,204 underlying)
Footnotes (3)
- [F1]Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date.
- [F2]Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date.
- [F3]Shares held by OrbiMed Capital GP VI LLC ("GP VI"). GP VI is the general partner of OrbiMed Private Investments VI, LP ("OrbiMed VI"). OrbiMed Advisors LLC ("Advisors") is the managing member of GP VI. By virtue of such relationship, GP VI and Advisors may be deemed to have voting and investment power with respect to the shares held by OrbiMed VI and as a result may be deemed to have beneficial ownership of such shares. Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. This report shall not be deemed an admission that the reporting person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Documents
Issuer
SpringWorks Therapeutics, Inc.
CIK 0001773427
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001682115
Filing Metadata
- Form type
- 4
- Filed
- Sep 18, 8:00 PM ET
- Accepted
- Sep 19, 7:12 PM ET
- Size
- 16.1 KB